Colorectal cancers with mutations in the p53 gene have an invasive property, but its underlying mechanism is not fully understood. Through the screening of two data sets of the genome-wide expression profile, one for p53-introduced cells and the other for the numbers of cancer tissues, we report here X-linked ectodermal dysplasia receptor (XEDAR), a member of the TNFR superfamily, as a novel p53 target that has a crucial role in colorectal carcinogenesis. p53 upregulated XEDAR expression through two p53-binding sites within intron 1 of the XEDAR gene. We also found a significant correlation between decreased XEDAR expressions and p53 gene mutations in breast and lung cancer cell lines (P ¼ 0.0043 and P ¼ 0.0122, respectively). Furthermore, promoter hypermethylation of the XEDAR gene was detected in 20 of 20 colorectal cancer cell lines (100%) and in 6 of 12 colorectal cancer tissues (50%), respectively. Thus, the XEDAR expression was suppressed to o25% of surrounding normal tissues in 12 of 18 colorectal cancer tissues (66.7%) due to either its epigenetic alterations and/or p53 mutations. We also found that XEDAR interacted with and subsequently caused the accumulation of FAS protein, another member of p53-inducible TNFR. Moreover, XEDAR negatively regulated FAK, a central component of focal adhesion. As a result, inactivation of XEDAR resulted in the enhancement of cell adhesion and spreading, as well as resistance to p53-induced apoptosis. Taken together, our findings showed that XEDAR is a putative tumor suppressor that could prevent malignant transformation and tumor progression by regulating apoptosis and anoikis.
Introduction
Identification and characterization of cancer-related genes are critical steps for the understanding of carcinogenic mechanisms. Among the cancer-related genes that have been identified so far, inactivation of the p53 gene is the most common alteration observed in human cancers (Beroud and Soussi, 2003; Hollstein et al., 1994) . In response to various types of cellular stress, including DNA damage, aberrant growth signal and oxidative stress, the p53 protein is stabilized and accumulated. Activated p53 regulates many target genes that induce cell-cycle arrest, apoptosis, DNA repair and cellular senescence (Levine, 1997; Vogelstein et al., 2000) . We have isolated a number of p53 target genes, including p53AIP1, p53R2 and p53RDL1 (Nakamura, 2004; Oda et al., 2000; Tanaka et al., 2000; Tanikawa et al., 2003) , and implicated the molecular mechanisms by which p53 regulated cell fate, death or survival, by balancing the expression levels of these genes. However, an entire picture of the p53 signaling pathway has not been disclosed yet.
In this study, to identify a p53 target gene(s) that is indispensable for p53-dependent tumor suppression, we used two data sets of the genome-wide expression profile obtained by cDNA microarray consisting of 36 864 cDNA fragments. One data set was obtained using the cells in which wild-type p53 was exogenously introduced, and the other was obtained using more than 1000 clinical cancer cases (Kidokoro et al., 2008; Kitahara et al., 2001) . Through the analysis of these two data sets, we identified XEDAR (X-linked ectodermal dysplasia receptor, also known as EDA2R and TNFRSF27) as a novel p53 target, which mediated important p53 functions.
The X-linked ectodermal dysplasia receptor is a member of the TNFR superfamily that is divided into two subgroups because of difference in their cytoplasmic region. One class of TNFR, a death receptor, contains a cytoplasmic death domain. Several death receptors, such as FAS, and four TRAIL receptors, DR4, DR5, DcR1 and DcR2, were shown to be regulated by p53 (Liu et al., 2005; Wu et al., 1997) and their physiological roles in carcinogenesis have been well characterized (Lee et al., 1999; Takakuwa et al., 2002) . XEDAR belongs to the other class of TNFR that lacks a discernible death domain. This class of TNFRs interacts with TRAFs (TNFR-associated factors) and activates the nuclear factor-kB (NF-kB) signaling, and consequently promotes cell proliferation. On the other hand, some members of this subclass were indicated to be involved in apoptotic pathways (Afford et al., 1999) . Thus, the TNFR superfamily is involved in various signaling pathways, including immune response, inflammation, development and carcinogenesis.
EDA-A1 and EDA-A2 are two major splicing isoforms of EDA, and EDA-A2 specifically binds to XEDAR (Yan et al., 2000) . EDA-A1 binds to EDAR and has an essential role for proper formation of skin appendages, as the mutations of EDA, EDAR or its adaptor protein EDARADD were shown to cause hypohidrotic ectodermal dysplasia (Smahi et al., 2002) . XEDAR is highly expressed in epidermal tissues during embryogenesis (Yan et al., 2000) , and mice that lacked TRAF6, an adaptor protein of XEDAR, also displayed hypohidrotic ectodermal dysplasia (Naito et al., 2002) . However, any mutations in the XEDAR gene have not been reported in individuals with hypohidrotic ectodermal dysplasia, and XEDAR-deficient mice were indistinguishable from their wild-type littermates at birth (Newton et al., 2004) . Thus, the physiological function of XEDAR has not been well clarified so far.
In this study, we report that XEDAR is frequently inactivated in human colorectal cancers, and its inactivation caused resistance to p53-induced apoptosis and enhancement of cell adhesion. Thus, our findings suggested the crucial role of XEDAR in the anoikis pathway. In a multistep genetic model for colorectal cancer, p53 mutations are more commonly found in invasive colon cancer tissues (Vogelstein et al., 1989) , but the mechanisms by which p53 inhibits metastasis have not been fully elucidated (Ilic et al., 1998; Nikiforov et al., 1996) . We show the novel mechanism that p53 suppresses colorectal carcinogenesis and tumor progression by regulating a novel p53 target, XEDAR.
Results

Identification of XEDAR as a p53 target gene
To fully uncover p53 target genes, we examined a total of 36 864 cDNA fragments by means of cDNA microarray using mRNAs isolated from U373MG p53 mutant glioblastoma cells that were infected with adenovirus designed to express wild-type p53 (Ad-p53) or LacZ (Ad-LacZ) (Tanikawa et al., 2003) . Thus, we found a total of 60 novel p53 target genes that were upregulated by the exogenous introduction of wild-type p53. We then examined the expression profile database constructed by the same set of cDNA microarray using various cancers (Kitahara et al., 2001) and selected XEDAR for further biological analysis because of its frequent downregulation in colorectal cancer tissues. To validate its regulation by p53, we carried out quantitative real-time PCR analysis and northern blot analysis and found that the XEDAR expression was remarkably induced by the introduction of p53 but not by that of LacZ (Figure 1a) . Moreover, XEDAR protein was increased by Ad-p53 infection in a dose-dependent manner (Supplementary Figure 1) . We also investigated the induction of XEDAR by DNA damage using MCF7 (breast cancer) and A549 (lung cancer) cells with wildtype p53. We found that Adriamycin treatment remarkably induced the XEDAR expression in both cells, indicating the p53-dependent regulation of XEDAR expression ( Figure 1b) .
Subsequently, we surveyed the genomic sequence of the XEDAR gene that is located on chromosome Xq12 and found two putative p53-binding regions (p53BR1 and p53BR2) within the first intron ( Figure 1c) . To examine the possible binding of p53 to these DNA segments, we carried out a chromatin immunoprecipitation (ChIP) assay using U373MG cells that were infected with either Ad-p53 or Ad-LacZ. A PCR analysis of immunoprecipitated DNA indicated that the p53 protein bound to the genomic fragment, including p53BR1 ( Figure 1c) . We then subcloned a DNA fragment of 466 base pairs corresponding to p53BR1, which included four putative p53-binding sequences (BS-A to D, respectively, Figure 1d ) into the pGL3 promoter vector (pGL3/p53BR1) (Promega, Madison, WI, USA). We found that the co-transfection of pGL3/p53BR1 with wild-type p53 expression plasmid enhanced the luciferase activity more than 40-fold, whereas the base substitutions within BS-A and BS-B segments completely diminished the luciferase activity (Figures 1c and d) . The result of ChIP analysis suggested the weak association of p53 with p53BR2, but co- 
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XEDAR as a p53-induced regulator of anoikis C Tanikawa et al transfection of p53 with pGL3/p53BR2 did not enhance the luciferase activity ( Figure 1c ). These findings indicated that p53 directly regulated the XEDAR expression through two p53-responsible elements, BS-A and BS-B.
Expression of XEDAR was frequently suppressed in colorectal cancer We then analyzed the expression level of XEDAR in 83 cell lines (20 of colorectal cancer, 22 of breast cancer, 35 of lung cancer and 6 control cell lines) and 26 normal adult tissues (Supplementary Table 2 ). We also examined cDNA sequences of p53 using mRNAs isolated from these cancer cells. As we expected, XEDAR expressions were significantly reduced in p53 mutant breast and lung cancer cells compared with p53 wildtype cancer cells (P ¼ 0.0043 and P ¼ 0.0122, respectively), as well as 6 normal cell lines and 26 normal adult tissues ( Figure 2a ). In addition, when we treated HEK293 and NHDF cells with siRNA oligonucleotide designed to suppress p53 (sip53), we found that XEDAR expression levels were remarkably decreased ( Figure 2b ). These data clearly implicated that the inactivation of p53 would cause the downregulation of XEDAR. However, for colorectal cancer cell lines, XEDAR expressions were reduced even in the cells without p53 mutations. Therefore, we considered there might be another mechanism that suppressed the XEDAR expression. Transcriptional silencing of tumor suppressor genes by DNA hypermethylation is a common epigenetic event in malignancies. We sequenced genomic DNA isolated from colorectal cancer cell lines and clinical tissues after bisulfate treatment and found tumor-specific hypermethylation of CpG islands (À190/ þ 73) in all of the 20 cancer cell lines and in half of the colorectal cancer tissues obtained from 12 male patients ( Figure 2c ). We then treated seven colorectal cancer cell lines with the demethylating agent 5-aza-2 0 -deoxycytidine and observed a significant restoration of the XEDAR expression in three of the four colorectal cancer cell lines with wild-type p53 background but not in any of the three p53 mutant cell lines (Figure 2d ), indicating that epigenetic alternations contribute to the reduced XEDAR expression in colorectal cancer cells. We also found the partial restoration of XEDAR protein expression in 5-aza-2 0 -deoxycytidine-treated HCT116 cells (Supplementary Figure 2) . We further measured quantitatively the XEDAR expression in colorectal cancer tissues and its corresponding normal tissues microdissected from 18 frozen clinical samples. We found its decreased expression (o25% of its corresponding normal tissue) in 12 colorectal cancer tissues (66.7%) (Figure 2e ).
We then examined genomic DNAs from 68 colorectal cancer tissues and 20 colorectal cancer cell lines. We identified one somatic mutation at the splice acceptor site (IVS3 À1 G>A) in one female clinical colorectal cancer case and one missense mutation (exon 2 A74C; Y8H) in one colorectal cancer cell line, NCI-H716 (derived from a male patient) (Figure 2f ). These base substitutions were found in none of the normal control tissues in the 68 patients or 96 normal healthy individuals examined. The splicing site mutation would cause the aberrant splicing of XEDAR transcript and dysfunction of the XEDAR protein. The data shown above indicated a possible role of XEDAR as a colorectal tumor suppressor.
Role of XEDAR in anoikis
We then carried out immunocytochemical analysis and found that the ectopically expressed XEDAR was accumulated at the leading edge in cells that exhibited process formation ( Figure 3a) . As the p53 gene mutation was associated with invasive colorectal cancer, we suspected that the inactivation of XEDAR might cause anchorage independency. To further investigate the role of XEDAR in cell adhesion or cell attachment, we transfected HEK293 cells with siRNA oligonucleotides designed to suppress XEDAR (siXEDAR) or EGFP (siEGFP) for 48 h and resuspended and plated in fresh culture dishes, as previously described (Figure 3b ) (Liang et al., 2007) . We investigated the morphological change of each cell and found that siXEDAR-treated HEK293 cells indicated increased cell adhesion (4 h after plating) and process formation (12 h) compared with the control cells (Figure 3b ). These findings suggested the XEDAR as a p53-induced regulator of anoikis C Tanikawa et al inhibitory effects of XEDAR on cell adhesion and/or motility. The presence of the p53 mutation was indicated to be significantly correlated with metastasis and poor prognosis of various cancers (Diez et al., 2000; Pharoah et al., 1999 XEDAR as a p53-induced regulator of anoikis C Tanikawa et al key role in the metastatic property of p53-mutated cancer. We then carried out a colony formation assay in soft agar using cancer cell lines with low or absent expression of XEDAR (DLD-1, HCT116, SW480, SW620 and H1299 cells) and found that XEDAR could suppress anchorage-independent tumor cell growth (Figure 3c ). Thereafter, we examined the involvement of XEDAR in detachment-induced apoptosis. Fortyeight hours after transfection with plasmid expressing XEDAR, HEK293 cells were detached and cultured in suspension for 24 h using a poly-2-hydroxyethyl methacrylate-coated plate (Folkman and Moscona, 1978) . Subsequent analyses indicated that XEDAR introduction reduced the number of viable cells through caspase-3 activation (Figure 3d ). Thus, we showed the significant role of XEDAR in detachment-induced apoptosis, namely anoikis.
Regulation of FAS and FAK by XEDAR in a p53-dependent apoptotic pathway
We then investigated the role of XEDAR in the p53-downstream pathway. A recent analysis indicated that p53 suppressed FAK expression (Golubovskaya et al., 2008) , one of the essential components in focal adhesion. Ectopic expression of FAK could enhance cell adhesion and attachment in various cancer cells (Ilic et al., 1995) similar to the XEDAR knockdown cells. Therefore, we examined the effect of XEDAR on FAK expression. Interestingly, introduction of XEDAR remarkably suppressed FAK expression (Figure 3d ), and downregulation of XEDAR in Ad-p53-infected U373MG cells or H1299 cells partially diminished FAK suppression by p53 (Figure 4a ). These results indicated the role of XEDAR in the negative regulation of FAK by p53. As XEDAR was shown to induce apoptosis through the activation of caspase-8, which is a key mediator of FAS-induced apoptotic signaling (Sinha and Chaudhary, 2004) , we investigated the physiological and functional interactions between FAS and XEDAR. Downregulation of XEDAR in p53-infected U373MG cells remarkably suppressed FAS induction (Figure 4a ), whereas p21 expression was not affected. A similar result was observed in XEDAR-suppressed HEK293 and NHDF cells (Figure 4b and Supplementary  Figure 3) . In addition, when XEDAR protein was overexpressed in HEK293 cells, the expression of endogenous FAS protein was significantly increased (Figure 4b) . Furthermore, knockdown of FAS also suppressed the expression of XEDAR (Figure 4b ). Coimmunoprecipitation or immunocytochemical analysis showed a physiological interaction of XEDAR and FAS at the plasma membrane (Figure 4c ). These results suggested that the XEDAR-FAS interaction was likely to cause stabilization of both proteins and subsequently promote apoptotic pathway.
Finally, we examined the role of XEDAR in the p53-induced apoptosis. Introduction of p53 into U373MG cells induced cell rounding and process retraction before apoptotic cell death, whereas siXEDAR-treated cells maintained spindle-shape morphology and subsequently attenuated Ad-p53-induced apoptosis (Figure 4d ). In addition, treatment with siXEDAR significantly inhibited adriamycin-induced growth suppression in MCF7 cells (Figure 4d ).
Taken together, XEDAR controlled apoptosis signaling and cell adhesion through the functional interaction and regulation of FAS and FAK, and XEDAR inactivation possibly resulted in the invasive property of p53-mutant cancer cells. Our findings showed a novel mechanism that prevents malignant transformation and tumor progression by the p53/XEDAR pathway ( Figure 5 ).
Discussion
Our microarray analysis identified dozens of uncharacterized possible p53 target genes, which might mediate important p53 functions. Some p53 target genes, such as p21 and BAX, which have significant roles in p53-dependent tumor suppression were downregulated in cancer tissues (Furutani et al., 1997; Rampino et al., 1997) . Therefore, the expression analysis of candidate p53 target genes in cancer tissues offers valuable information for their possible roles in human carcinogenesis.
XEDAR is highly expressed in embryonic tissues, and the mutation of the EDA gene that encodes its ligand EDA-A2 caused hypohidrotic ectodermal dysplasia. In addition, we found that XEDAR was a direct transcriptional target of p63, a member of the p53 family, which has an important role in epidermal development (data not shown). However, the evidence obtained so far (Sinha et al., 2002) . On the other hand, the EDA-A2/ XEDAR pathway was also shown to promote apoptotic cell death through the DISC (death-inducing signaling complex) formation containing FADD, caspase-8, caspase-10 and c-FLIP (Sinha and Chaudhary, 2004) . However, XEDAR lacks a discernible death domain; the molecular mechanism of XEDAR-induced apoptosis was not well understood. Some TNFR members that lacked the death domain were shown to induce apoptosis through the interaction with FAS, another p53-inducible TNFR superfamily member (Afford et al., 1999; Grell et al., 1999) . Similarly, our result suggested that XEDAR promoted apoptotic signaling through the interaction with FAS. We also examined the effect of FAS and XEDAR on NF-kB signaling; however, coexpression of XEDAR and FAS did not enhance the NF-kB pathway (data not shown), indicating that the XEDAR-FAS interaction would rather promote apoptotic signaling than NF-kB-mediated cell proliferation.
We also found that XEDAR negatively regulated FAK, which is a major mediator of cell adhesion and functions as an adaptor protein that transduces adhesion-dependent and growth factor-dependent signaling (McLean et al., 2005) . FAK expression was frequently increased in various cancer tissues, including colorectal cancer, and its upregulation was associated with poor prognosis and anoikis resistance (Lark et al., 2003; Owens et al., 1995; Weiner et al., 1993) . Metastasis occurs through a series of sequential steps in which tumor cells first migrate from the primary tumor, penetrate blood vessels and colonize distant sites. Among them, the metastatic potential of tumors is generally associated with an increased resistance to anoikis during the initial step of cell migration. Our findings indicated that XEDAR inactivation would cause FAS suppression and FAK activation and subsequently confer anoikis resistance in cancer cells.
We also found three mechanisms that inactivated XEDAR in colorectal cancer cells. One mechanism was p53 mutations that were found in nearly half of the colorectal cancers (Beroud and Soussi, 2003) . The second one was inactivation by the promoter hypermethylation that was also observed in half of the colorectal cancer tissues and in all of the colorectal cancer cell lines. The fact that treatment with 5-aza-2 0 -deoxycytidine restored XEDAR expression in none of the p53 mutant colorectal cancer cell lines indicated that either the p53 mutation or promoter hypermethylation is sufficient to suppress the XEDAR expression. In addition, we found, although rare, genetic mutations that would cause the inactivation of XEDAR in colorectal cancers. Taken together, our findings indicated that XEDAR is a putative colorectal tumor suppressor that would prevent the malignant transformation and tumor progression by the cross-talk between FAS and FAK.
Materials and methods
cDNA microarray cDNA microarray analysis was carried out as previously described (Kitahara et al., 2001; Mori et al., 2002) . Briefly, colorectal cancer tissues or its surrounding normal mucosa that were obtained with informed consent were microdissected from frozen tissue sections. The total RNA of each sample was isolated and amplified using RNeasy spin column kits (Qiagen, Valencia, CA, USA) and T7-Transcription kit (Epicentre Technologies, Madison, MI, USA). Replication-deficient recombinant adenovirus encoding p53 (Ad-p53) or LacZ (Ad-LacZ) was generated and purified, as previously described (Oda et al., 2000) . U373MG cells were infected with viral solutions at an indicated multiplicity of infection and incubated at 37 1C until the time of harvest. poly(A) þ RNAs were isolated from U373MG cells using a standard protocol. Each RNA sample was labeled and hybridized to a microarray consisting of 36 864 cDNA fragments. The microarray data set is accessible from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/index.cgi, Accession No. GSE14953).
Cell culture and transfections
Each cell line was purchased from the American Type Culture Collection (Manassas, VA, USA), Lonza Biologics (Portsmouth, NH, USA) or JCRB (Osaka, Japan). Cells were transfected with plasmids using FuGENE6 (Roche, Basel, Switzerland) or Lipofectamine LTX (Invitrogen, Carlsbad, CA, USA). siRNA oligonucleotides, commercially synthesized by Sigma Genosis (St Louis, MO, USA), were transfected with Lipofectamine 2000 reagent (Invitrogen) for 4 h. Sequences for each oligonucleotide are indicated in Supplementary Table 1. For suspension culture, 6-well plates were coated with 2 ml of poly-HEMA (poly-2-hydroxyethyl methacrylate; Sigma, St Louis, MO, USA) solution in ethanol (10 mg/ml) for at least 3 days until the solvent had evaporated completely. The cells were suspended in 2 ml of media containing 0.5% methylcellulose and plated onto poly-HEMA-coated dishes. For methylation analysis, the cells were treated with an indicated dosage of 5-aza-2 0 -deoxycytidine (Sigma). Quantitative real-time PCR Quantitative real-time PCR was conducted using the SYBR Green I Master or Probe Master on a LightCycler 480 (Roche). The primer and probe sequences are indicated in Supplementary Table 1 . The mRNA of 26 normal tissues was purchased from TAKARA Clontech (Kyoto, Japan).
ChIP assay
Chromatin immunoprecipitation assay was carried out using the CHIP Assay kit (Upstate Biotechnology, Waltham, MA, USA) as previously described (Tanikawa et al., 2003) . PCR amplifications of XEDAR intron 1, containing the consensus p53-binding sites, were performed on immunoprecipitated Gene reporter assay DNA fragments, including potential p53-binding sites of the XEDAR gene, were amplified and subcloned into the pGL3-promoter vector (Promega). The primers for amplification are indicated in Supplementary Table 1 . To make a series of mutant vectors, a point mutation 'T' was inserted into the site of the fourth and the fourteenth nucleotide 'C' and into the seventh and the seventeenth nucleotide 'G' of the consensus p53-BS using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). A reporter assay was carried out using the Dual Luciferase assay system (Promega) as previously described (Oda et al., 2000) .
Bisulfite sequencing analysis Genomic DNA of 3 mg was digested for 16 h with 30 U of Sau3AI (Takara, Tokyo, Japan) in a 150 ml of reaction volume. The digested DNA was denatured in 0.3 M of NaOH for 20 min at 37 1C, and then the unmethylated cytosine residues were sulfonated by incubation in 3.12 M of sodium bisulfite (pH 5.0) and 0.5 mM of hydroquinone at 55 1C for 16 h. The sulfonated DNA was recovered using the QIAquick PCR purification system (Qiagen) according to the manufacturer's recommendations. The conversion reaction was completed by desulfonating in 0.3 M of NaOH for 20 min at 37 1C. The DNA was ethanol precipitated and resuspended in double-distilled water. The modified DNA was subjected to PCR amplification of the CpG islands in the XEDAR promoter using the primers indicated in Supplementary Table 1 . Amplified products were subcloned using the TOPO-TA Cloning System (Invitrogen). Plasmid DNA of at least six insert-positive clones was isolated and sequenced using the ABI sequencing system (Applied Biosystems, Foster City, CA, USA).
Mutation analysis
The entire coding region of the p53 gene was amplified by PCR using cDNA prepared from 77 cancer cell lines, and PCR products were directly sequenced. For analysis in the XEDAR gene, genomic DNA was purified by standard protocol. Six coding exons of the XEDAR gene were amplified, purified and sequenced. The primers used in this analysis are indicated in Supplementary Table 1 .
Antibodies Anti-Flag monoclonal (clone M2) and polyclonal (F7425) antibody, as well as anti-b-actin monoclonal antibody (clone AC15) were purchased from Sigma. Anti-p53 monoclonal antibody (Ab-12, clone DO-7) and anti-p21 WAF1 monoclonal antibody (Ab-1, clone EA10) were purchased from Calbiochem (San Diego, CA, USA). Anti-XEDAR polyclonal antibody (T-14), anti-FAS monoclonal antibody (B-10), anti-HA monoclonal (F-7) and polyclonal (Y-11) antibody, as well as anti-c-Myc polyclonal antibody (A-14) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-HA monoclonal antibody (clone 3F10) was purchased from Roche. Anti-FAK polyclonal antibody (ab2999) was purchased from Abcam (Cambridge, UK). Rabbits were immunized with the recombinant proteins corresponding to the extracellular domain (amino acids 1-139) of XEDAR. Antibodies were subsequently purified on antigen affinity columns. For labeling F-actin, Alexa fluor 594 phalloidin (Molecular Probes, Eugene, OR, USA) was used.
Spreading assay and processing morphogenesis Forty-eight hours after transfection with each siRNA oligonucleotide, HEK293 cells were detached with 0.02% ethylenediaminetetraacetic acid (EDTA), resuspended in Dulbecco's modified Eagle's medium (DMEM) with 10% of fetal bovine serum and plated onto 6-well plates. Spreading cells were counted after 4 h of incubation, and processing morphogenesis was determined 12 h later.
Anchorage-independent growth assay Soft agar assays were carried out in 6-well culture plates. A volume of 2 ml of culture media with 0.5% agar was solidified in the bottom of each well. At 24 h after transfection with either plasmid, equal numbers of cells were suspended in 1.5 ml of media with 0.33% agar and added to each well. Cells were fed with 1 ml of media supplement with geneticin (Invitrogen) every 3 days. After 2 weeks of incubation, colonies were stained with iodonitrotetrazolium chloride (Sigma) and scored using the Image J software.
Cell death assay Cells were incubated with adriamycin for 2 h or infected with either Ad-p53 or Ad-LacZ at 6 h after transfection of siRNA oligonucleotide. Apoptotic cells were quantified by FACS analysis as previously described (Matsuda et al., 2002) . Activities of caspase-3 were monitored using a caspase-3 assay kit (MBL, Nagoya, Japan). Cell viability was determined using the MTT assay using Cell Counting Kit-8 (Dojindo, Kumamoto, Japan).
